Dec 11 (Reuters) - The U.S. Food and Drug Administration has approved Flow Neuroscience's at-home brain stimulation device to treat depression, offering an alternative to typical antidepressants that ...

The FDA has approved its first at-home, nondrug therapy for depression, with a wearable brain stimulation headset developed by Flow Neuroscience. The agency issued a green light that covers the device ...

A controversy is swirling at a Texas university. The trigger? A flowchart. On Dec. 1, the new chancellor of the Texas Tech University system sent professors a diagram laying out a chain of approval ...

Send a note to Doug Wintemute, Kara Coleman Fields and our other editors. We read every email. By submitting this form, you agree to allow us to collect, store, and potentially publish your provided ...

Attention! Another new term has entered the TikTok lexicon, and you’re about to see it everywhere. If you’ve spent any time on the app within the past week, you might have noticed people talking about ...

Bengaluru: Meesho has pulled ahead of its consumer internet peers on free cash flow in FY25, underscoring a shift in India’s e-commerce sector from chasing growth to focusing on capital-efficient ...

A recent study revealed that almost 90% of stock market traders experience financial losses during their trading journeys. This statistic highlights the challenges and inherent risks associated with ...

There comes a time before every big purchase when you might ask yourself, “Do I really need this?” If you don’t pause for a moment — and if you tend to blow your budget as a result — then you need to ...

Chart Industries and Flowserve recently agreed to merge in an all-stock deal. The two companies outlined significant revenue and cost synergies. Strangely, both bargain-priced stocks fell after the ...

The all-stock merger between Chart and Flowserve was greeted with a material sell-off. On paper, the deal makes sense: synergies are valuable, the portfolio is diversified, and valuation now is ...